Cognitive Walking + Brain Stimulation for Older Adults
Trial Summary
What is the purpose of this trial?
Declines in cognitive function and walking function are highly intertwined in older adults. A therapeutic approach that combines complex (cognitively engaging) aerobic walking exercise with non-invasive electrical brain stimulation may be effective at restoring lost function. This study tests whether electrical stimulation of prefrontal brain regions is more beneficial than sham stimulation.
Will I have to stop taking my current medications?
The trial requires that you stop taking medications that are thought to influence tDCS (a type of brain stimulation) neuroplasticity (the brain's ability to change).
What data supports the effectiveness of the treatment Cognitive Walking + Brain Stimulation for Older Adults?
Research suggests that transcranial direct current stimulation (tDCS) targeting the prefrontal cortex can improve walking performance in older adults, especially when combined with walking exercises. Studies have shown that tDCS may enhance neural efficiency and improve complex walking tasks, indicating potential benefits for mobility and cognitive function.12345
Is transcranial direct current stimulation (tDCS) safe for older adults?
How is the Cognitive Walking + Brain Stimulation treatment different from other treatments for older adults?
This treatment is unique because it combines transcranial direct current stimulation (tDCS) with walking exercises to improve both cognitive and motor functions in older adults. Unlike other treatments that may focus solely on physical or cognitive aspects, this approach targets the brain's prefrontal cortex to enhance dual-task walking, which involves walking while performing a cognitive task, potentially improving overall neural efficiency.12369
Research Team
David J Clark, ScD
Principal Investigator
University of Florida
Eligibility Criteria
This trial is for older adults, aged 65 and above, who have noticed a decline in their memory or cognitive abilities over the past year. Participants should be able to walk on their own for six minutes, even if they need to use a cane.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive complex walking exercise combined with either active or sham tDCS for 18 sessions over a 6-week period
Follow-up
Participants are monitored for changes in executive function and walking speed post-intervention
Treatment Details
Interventions
- Prefrontal Active tDCS (Neuromodulation)
- Prefrontal Sham tDCS (Neuromodulation)
- Walking Exercise (Behavioural Intervention)
Prefrontal Active tDCS is already approved in Canada for the following indications:
- Depression
- Chronic Pain
- Stroke Rehabilitation
- Cognitive Enhancement
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
Dr. Stephen J. Motew
University of Florida
Chief Executive Officer since 2024
MD cum laude from the University of Illinois at Chicago School of Medicine, Master's in Healthcare Administration from the University of North Carolina at Chapel Hill
Dr. Timothy E. Morey
University of Florida
Chief Medical Officer since 2023
MD and Bachelor's from the University of Florida
National Institute on Aging (NIA)
Collaborator
Dr. Richard J. Hodes
National Institute on Aging (NIA)
Chief Executive Officer since 1993
MD from Harvard Medical School
Dr. Marie Bernard
National Institute on Aging (NIA)
Chief Medical Officer
MD from Harvard Medical School